Evidence map›Paper›PMID 36090974›Full record

ReviewFrontiers in immunology2022

Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.

Tao Huang, Lushan Peng, Yingying Han, Dan Wang, Xiaoyun He, Junpu Wang, Chunlin Ou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 69 citations in OpenAlex.

  1. Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tao HuangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Lushan PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Yingying HanDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Dan WangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Xiaoyun HeDepartments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, China.
Junpu WangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Chunlin OuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) vaccines constitute an emerging therapeutic method with the advantages of high safety and efficiency as well as easy synthesis; thus, they have been widely used in various human diseases, especially in malignant cancers. However, the mRNA vaccine technology has some limitations, such as instability and low transitive efficiency

Indexed as

NanoparticlesNeoplasmsHumansLiposomesmRNA VaccinesVaccines, SyntheticLipid NanoparticlesLiposomesmRNA VaccinesVaccines, Syntheticcancer therapydelivery systemmRNA vaccinenanocarriertherapeutic target

Identifiers

PMID36090974
PMCPMC9458914
OpenAlexW4293217701

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.